ES
ESTA.US Establishment Labs Holdings Inc
- Market cap
- USD 2.11B
- P/E
- -
- P/B
- 131.24x
- ROE
- -306.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ESTA.US undervalued?
Graham numberThe Graham number of Establishment Labs Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Establishment Labs Holdings Inc fundamental analysis
No fundamental analysis for Establishment Labs Holdings Inc yet.
Establishment Labs Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Establishment Labs Holdings Inc
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales…
Full company profileEstablishment Labs Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Establishment Labs Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.8M | 34.7M | 61.2M | 89.6M | 84.7M | 127M | 162M | 165M | 166M | 211M | 266M |
| Gross Profit | 10.1M | 17.7M | 36.1M | 54.9M | 52.5M | 85.4M | 107M | 107M | 110M | 146M | 186M |
| Operating Income | -15.8M | -20.0M | -23.9M | -30.9M | -27.9M | -25.1M | -39.7M | -65.0M | -50.0M | -39.0M | -17.9M |
| EBITDA | -18.0M | -22.4M | -9.26M | -25.5M | -24.9M | -26.5M | -56.7M | -58.3M | -56.2M | -22.3M | -11.5M |
| Net Income | -22.2M | -34.9M | -21.1M | -38.2M | -38.1M | -41.1M | -75.2M | -78.5M | -84.6M | -51.1M | -47.8M |
| EPS | -1.20 | -1.89 | -1.22 | -1.86 | -1.63 | -1.72 | -3.08 | -3.07 | -3.00 | -1.72 | -1.57 |
| Balance Sheet | |||||||||||
| Total Assets | 29.6M | 57.1M | 117M | 117M | 156M | 140M | 211M | 269M | 347M | 357M | 359M |
| Total Liabilities | 56.0M | 62.1M | 47.1M | 76.9M | 81.4M | 88.8M | 219M | 250M | 294M | 334M | 343M |
| Shareholders' Equity | -26.4M | -5.01M | 69.5M | 39.6M | 75.0M | 50.7M | -8.19M | 18.4M | 53.1M | 23.5M | 15.6M |
| Cash & Short-term Investments | 479K | 10.9M | 52.6M | 37.7M | 84.5M | 53.4M | 66.4M | 40.0M | 90.3M | 75.6M | 75.8M |
| Total Debt | 38.1M | 24.1M | 27.5M | 48.4M | 52.5M | 54.2M | 179M | 192M | 225M | 264M | 270M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.3M | -32.0M | -33.9M | -30.0M | -12.5M | -27.5M | -52.2M | -88.5M | -58.5M | -50.9M | -17.6M |
| Capital Expenditure | 10.6M | 941K | 1.77M | 7.00M | 3.91M | 6.73M | 34.3M | 24.5M | 15.6M | 6.72M | 8.53M |
| Free Cash Flow | -24.8M | -32.9M | -35.7M | -37.0M | -16.4M | -34.3M | -86.4M | -113M | -74.1M | -57.6M | -26.1M |
| Ratios | |||||||||||
| ROE | - | - | -30.4% | -96.3% | -50.9% | -81.1% | - | -426.8% | -159.3% | -216.9% | -306.4% |
| ROA | -75.0% | -61.1% | -18.1% | -32.7% | -24.4% | -29.5% | -35.6% | -29.2% | -24.4% | -14.3% | -13.3% |
| Net Profit Margin | -111.9% | -100.6% | -34.5% | -42.6% | -45.0% | -32.5% | -46.5% | -47.5% | -51.0% | -24.2% | -18.0% |
| Debt to Equity | - | - | 0.40x | 1.22x | 0.70x | 1.07x | - | 10.45x | 4.24x | 11.23x | 17.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Establishment Labs Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 3.87M | 0.16 | - |
| 2021 | USD 4.23M | 0.18 | - |
| 2020 | USD 154K | 0.01 | - |
| 2019 | USD 1.72M | 0.08 | - |
| 2018 | - | - | - |
| 2017 | USD 36.1M | 1.95 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Establishment Labs Holdings Inc
- Insiders 10.03%
- Institutions 89.97%
- Public & others 0.00%
- Shares outstanding 29.8M
- Free float 19.8M
Top funds holding ESTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 687K | 2.30% | 0.00% | Oct 2026 |
| T. Rowe Price New Horizons | 525K | 1.76% | +7.39% | Sep 2026 |
| Loomis Sayles Small Cap Growth Instl | 489K | 1.64% | 0.00% | Sep 2026 |
| Putnam Small Cap Growth A | 407K | 1.37% | 0.00% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 388K | 1.30% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 296K | 0.99% | +0.13% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 254K | 0.85% | -0.38% | Oct 2026 |
| William Blair Small Cap Growth I | 235K | 0.79% | +10.29% | Sep 2026 |
| T. Rowe Price Health Sciences | 234K | 0.78% | 0.00% | Sep 2026 |
| American Funds SMALLCAP World A | 232K | 0.78% | +26.13% | Sep 2026 |
| Principal SmallCap Growth I Instl | 199K | 0.67% | -0.11% | Sep 2026 |
| Brown Advisory Small-Cap Growth Inv | 198K | 0.66% | -1.83% | Sep 2026 |
| Brown Advisory US SmlrComs Dollar B Acc | 177K | 0.59% | 0.00% | Sep 2026 |
| CREF Total Global Stock Account R3 | 168K | 0.56% | +41.92% | Aug 2026 |
| Vanguard Russell 2000 ETF | 158K | 0.53% | +1.15% | Sep 2026 |
| Royce Small-Cap Trust | 149K | 0.50% | -0.42% | Sep 2026 |
| Royce Small-Cap Fund Invmt | 127K | 0.43% | -0.41% | Sep 2026 |
| Vanguard Explorer Inv | 125K | 0.42% | +12.06% | Sep 2026 |
| Hood River International Opp Instl | 117K | 0.39% | +34.57% | Jun 2026 |
| Royce Micro-Cap Trust | 115K | 0.39% | -1.86% | Sep 2026 |
Top institutions holding ESTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| JW Asset Management, LLC | 2.69M | 9.04% | -12.05% | Jun 2026 |
| RTW INVESTMENTS, LLC | 2.66M | 8.91% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.58M | 5.31% | +1,140.56% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.53M | 5.15% | 0.00% | Jun 2026 |
| Brown Advisory Holdings Inc | 1.31M | 4.41% | -14.00% | Jun 2026 |
| Findell Capital Management LLC | 1.10M | 3.68% | +9.85% | Jun 2026 |
| Mudita Advisors LLP | 723K | 2.43% | -5.43% | Jun 2026 |
| William Blair Investment Management, LLC | 714K | 2.40% | +3.65% | Jun 2026 |
| Rubric Capital Management LP | 688K | 2.31% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 672K | 2.25% | -19.36% | Jun 2026 |
| Franklin Templeton Inc | 614K | 2.06% | +156.55% | Jun 2026 |
| Bank of America Corp | 608K | 2.04% | +45.87% | Jun 2026 |
| Tyro Capital Management LLC | 606K | 2.03% | -47.40% | Jun 2026 |
| D. E. Shaw & Co LP | 567K | 1.90% | +39.02% | Jun 2026 |
| Rice Hall James & Associates, LLC | 561K | 1.88% | +2.23% | Jun 2026 |
| UBS Group AG | 549K | 1.84% | +271.78% | Jun 2026 |
| The Toronto-Dominion Bank | 540K | 1.81% | 0.00% | Jun 2026 |
| Summit Partners Public Asset Management, LLC | 491K | 1.65% | +25.12% | Jun 2026 |
| Royce & Associates, LP | 472K | 1.58% | +10.49% | Jun 2026 |
| State Street Corp | 455K | 1.53% | +908.90% | Jun 2026 |
Establishment Labs Holdings Inc company profile
- Company name
- Establishment Labs Holdings Inc
- Ticker
- ESTA.US
- ISIN
- VGG312491084
- Exchange
- USA Stocks
- Listed since
- Jul 19, 2018
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,004
- Fiscal year end
- December
- Address
- 11401 century oaks terrace, Austin, TX, United States, 78758
- Phone
- 800 924 5072
- Website
- establishmentlabs.com
About Establishment Labs Holdings Inc
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.
Establishment Labs Holdings Inc management
8- Mr. Fillipo Peter CaldiniCEO & Director · born 1965
- Mr. S. Ross MansbachGeneral Counsel & Chief Compliance Officer · born 1967
- Ms. Cassandra E. HarrisSenior VP & CFO · born 1973
- Mr. Roberto de MezervilleChief Technology Officer · born 1980
- Ms. Malavika WilliamVP, Global Head of Marketing & Communications
- Ms. Melissa Moreira AmadoVice President of Global Human Resources
- Mr. Ivan BilicSenior Vice President of Commercial Operations - OUS
- Mr. Jeff EhrhardtSenior VP & GM of North America